due for a big rally as the small pieces of positive build, valuation is ridiculous for a small cap with such a pipeline.
Most of Biotech in ASX have all enjoyed some rebounce recently, without any good new behind.
News: ACR Acrux Says Its Sixth Generic Application Accepted By U.S. FDA For Review, page-11
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.9¢ |
Change
-0.001(5.00%) |
Mkt cap ! $8.155M | |||
| Open | High | Low | Value | Volume |
| 2.0¢ | 2.0¢ | 1.9¢ | $12.39K | 620.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 421000 | 1.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.0¢ | 286349 | 2 |
View Market Depth
| Last trade - 11.30am 18/06/2025 (20 minute delay) ? |
| ACR (ASX) Chart |